We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+7.96%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$78.8B
AUM Growth
-$135M
(-0.17%)
Cap. Flow
-$4.13B
Cap. Flow
% of AUM
-5.25%
Top 10 Holdings %
Top 10 Hldgs %
14.64%
Holding
3,669
New
809
Increased
1,002
Reduced
1,102
Closed
643
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$807M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$497M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$390M |
| 4 |
Kenvue
KVUE
|
+$379M |
| 5 |
Broadcom
AVGO
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$409M |
| 2 |
Visa
V
|
+$354M |
| 3 |
Advanced Micro Devices
AMD
|
+$328M |
| 4 |
Meta Platforms (Facebook)
META
|
+$317M |
| 5 |
Lockheed Martin
LMT
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.61% |
| 2 | Consumer Discretionary | 9.64% |
| 3 | Healthcare | 8.17% |
| 4 | Industrials | 8.1% |
| 5 | Financials | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Agios Pharmaceuticals
AGIO
$1.96B
| $17.3M | 0.02% |
635,069
+139,578
| +28% | +$4.9M |
|
752
Inspire Medical Systems
INSP
$1.73B
| $17.3M | 0.02% |
187,226
-427,133
| -70% | -$40.9M |
|
753
Clorox
CLX
$13.1B
| $17.2M | 0.02% |
170,958
-22,323
| -12% | -$2.42M |
|
754
AGCO
AGCO
$7.17B
| $17.2M | 0.02% |
164,973
+82,729
| +101% | +$8.8M |
|
755
GXO Logistics
GXO
$5.49B
| $17.2M | 0.02% |
326,550
-505,516
| -61% | -$26.6M |
|
756
State Street Energy Select Sector SPDR ETF
XLE
$39.6B
| $17.2M | 0.02% |
383,947
+133,913
| +54% | +$5.96M |
|
757
Iron Mountain
IRM
$36.4B
| $17.2M | 0.02% |
206,809
+57,880
| +39% | +$5.42M |
|
758
PUT
Revolution Medicines
RVMD
$43.9B
| $17.1M | 0.02% |
+215,000
| New | +$14.1M |
|
|
FLG
759
Flagstar Bank National Association
FLG
$5.83B
| $17M | 0.02% |
1,352,726
+1,253,590
| +1,265% | +$15M |
|
760
Murphy USA
MUSA
$10.2B
| $17M | 0.02% |
42,047
+41,365
| +6,065% | +$15.9M |
|
761
Affirm
AFRM
$25.5B
| $16.9M | 0.02% |
227,143
+131,732
| +138% | +$9.48M |
|
762
Urban Edge Properties
UE
$2.75B
| $16.9M | 0.02% |
+878,475
| New | +$17M |
|
763
Lumen
LUMN
$6.91B
| $16.9M | 0.02% |
+2,169,146
| New | +$17.9M |
|
|
WCC
764
WESCO International
WCC
$18.3B
| $16.7M | 0.02% |
68,286
-258,659
| -79% | -$63.4M |
|
|
WAY
765
Waystar Holding Corp
WAY
$4.72B
| $16.6M | 0.02% |
507,637
+290,766
| +134% | +$10.4M |
|
766
Hormel Foods
HRL
$13.4B
| $16.6M | 0.02% |
700,518
-890,289
| -56% | -$20.8M |
|
|
VISN
767
Vistance Networks Inc
VISN
$2.67B
| $16.6M | 0.02% |
914,872
-955,924
| -51% | -$16.5M |
|
768
Annexon
ANNX
$862M
| $16.6M | 0.02% |
3,299,256
+2,001,996
| +154% | +$7.65M |
|
|
FRMI
769
Fermi Inc
FRMI
$4.52B
| $16.5M | 0.02% |
+2,068,609
| New | +$40.4M |
|
770
SouthState Bank Corp
SSB
$10.6B
| $16.5M | 0.02% |
175,358
+159,556
| +1,010% | +$14.8M |
|
771
CytomX Therapeutics
CTMX
$745M
| $16.5M | 0.02% |
3,872,202
-40,879
| -1% | -$155K |
|
|
FIGR
772
Figure Technology Solutions
FIGR
$6.47B
| $16.5M | 0.02% |
403,310
-588,896
| -59% | -$23.6M |
|
773
California Resources
CRC
$4.89B
| $16.5M | 0.02% |
368,350
-630,435
| -63% | -$29.9M |
|
774
CALL
US Bancorp
USB
$100B
| $16.5M | 0.02% |
308,400
+270,200
| +707% | +$13.3M |
|
|
CDTX
775
PUT
DELISTED
Cidara Therapeutics
CDTX
| $16.4M | 0.02% |
+74,400
| New | +$12M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Balyasny Asset Management held 3,669 positions worth $78.8B, down 0.17% from $78.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Balyasny Asset Management withdrew a net $4.13B in Q4 2025, closing 643 positions and reducing 1,102 holdings. Its most notable exit was Mr. Cooper, an estimated $277M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Balyasny Asset Management opened a new position in Avidity Biosciences worth $436M.
- Balyasny Asset Management's largest Q4 2025 buy was Avidity Biosciences: 6,040,590 shares worth $436M.
- Balyasny Asset Management added most to Amazon in Q4 2025, an estimated $807M increase.
- Balyasny Asset Management's biggest Q4 2025 reduction was Apple, cutting an estimated $409M.
- Balyasny Asset Management fully exited Mr. Cooper in Q4 2025, selling an estimated $277M.
- Balyasny Asset Management's ten largest holdings make up 15% of its $78.8B portfolio in Q4 2025.
- Balyasny Asset Management opened 809 new positions and closed 643 in Q4 2025.
- Balyasny Asset Management's portfolio value fell 0.17% quarter-over-quarter to $78.8B.
Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.